Liquid Biopsy Biospecimens: Blood-Based Cancer Detection and Monitoring

The Liquid Biopsy Revolution in Cancer Detection

Liquid biopsy technologies analyze tumor-derived materials in blood as part of our broader oncology biospecimen portfolio. This enables non-invasive cancer detection, molecular characterization, treatment monitoring, and minimal residual disease surveillance. No tissue biopsies required for these applications across the United States.

Tumors continuously shed cellular and molecular components into circulation. Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), tumor-derived extracellular vesicles, and tumor-educated platelets each provide distinct windows into tumor biology. Accessible through minimally invasive blood draws, these analytes revolutionize precision oncology.

Precision approaches requiring comprehensive tumor genomic profiling become standard of care. Early cancer detection programs aim to identify malignancies at curable stages. Demand for high-quality plasma, serum, and whole blood intensifies.

Researchers developing liquid biopsy assays require biospecimens from cancer patients with confirmed diagnoses. Healthy controls establish specificity baselines. Benign disease controls exclude false positives. Longitudinal collections document molecular evolution and therapeutic response dynamics.

The natural history of cancer progression manifests in liquid biopsy analytes. Early-stage cancers shed minimal circulating material. Advanced tumors release abundant CTCs and ctDNA. Metastatic disease shows highest analyte levels. Therapeutic responses produce rapid decreases. Resistance emergence causes re-elevation.

From study design through receipt of samples collected at critical timepoints, proper biospecimen selection captures these dynamics. Pre-treatment samples establish baselines. On-treatment samples monitor responses. Progression samples reveal resistance mechanisms enabling real-time tumor evolution tracking.

Circulating Tumor DNA Analysis

Circulating tumor DNA comprises fragmented DNA molecules released from tumor cells into bloodstream. Tumor cell death through apoptosis or necrosis liberates genomic DNA. Active secretion contributes additionally. ctDNA comprises 0.01-10% of total cell-free DNA in plasma depending on tumor burden and biology.

Next-generation sequencing technologies detect tumor-specific mutations, copy number alterations, and epigenetic modifications in ctDNA. Digital PCR quantifies specific mutations with high sensitivity. Targeted sequencing panels profile actionable mutations. Whole exome or genome sequencing provides comprehensive molecular characterization though at lower depths.

ctDNA levels correlate strongly with tumor burden. Advanced cancers show higher ctDNA fractions than early-stage disease. Metastatic tumors release more DNA than localized disease. This enables ctDNA as a surrogate for disease volume tracking treatment responses and detecting minimal residual disease.

Mutation profiling in ctDNA reveals tumor heterogeneity. Different metastatic sites harbor distinct mutations. Serial sampling captures clonal evolution. Resistance mutations emerge under therapeutic pressure detectable in plasma before imaging progression.

Methylation patterns in ctDNA provide tissue-of-origin information. Cancer-specific methylation signatures enable tumor type identification from blood. This supports screening applications detecting multiple cancer types simultaneously from single blood draws across diverse patient populations.

Pre-analytical variables profoundly affect ctDNA recovery and analysis. Collection tube type influences cell-free DNA yields. Centrifugation protocols affect cellular DNA contamination. Storage conditions impact DNA fragmentation. Researchers require plasma samples processed under standardized conditions.

Sanguine’s Comprehensive Liquid Biopsy Biospecimen Solutions

Sanguine Bio provides end-to-end support for liquid biopsy research from study design through receipt of samples. Our direct-to-donor model and expanded donor network enable access to cancer patients across the United States with diverse tumor types, stages, and treatment histories.

Custom collection services accommodate specialized requirements. Plasma collection protocols for ctDNA analysis use cell-free DNA preservation tubes with standardized processing. Whole blood for CTC enumeration employs validated collection and transport procedures maintaining cell viability.

Access to hard-to-find populations distinguishes our offerings. Rare cancer types with limited patient numbers receive targeted recruitment. Specific disease stages from newly diagnosed through treatment-refractory enable comprehensive natural history coverage. Serial collections document longitudinal tumor evolution.

Comprehensive genomic annotation accompanies each sample. Tumor pathology reports, treatment histories, imaging findings, and clinical outcomes provide research context. Electronic medical records integration ensures data completeness and accuracy supporting correlative analyses.

Explore our oncology biospecimen portfolio or Check Our Inventory for available liquid biopsy biospecimens, or contact our scientific team to discuss custom collection projects meeting your specific research needs across oncology applications.

Ethical Sourcing and Compliance

All biospecimens undergo rigorous ethical sourcing procedures. Donors provide fully informed consent understanding research applications. IRB approval covers all collection activities. HIPAA compliance protects patient privacy throughout the United States.

Quality management systems ensure consistency. SOPs govern collection, processing, and storage. Regular audits verify compliance. Staff training maintains quality standards. Chain of custody documentation tracks specimens from collection through delivery.

Third-party testing validates infectious disease screening. Viral markers receive assessment. Bacterial contamination testing occurs. Quality certificates accompany shipments. This ensures researcher safety and experimental validity across all applications.

References

1. Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223-238. doi:10.1038/nrc.2017.7
2. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531-548. doi:10.1038/nrclinonc.2017.14
3. Rolfo C, Mack P, Scagliotti GV, et al. Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021;16(10):1647-1662. doi:10.1016/j.jtho.2021.06.017
4. Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570(7761):385-389. doi:10.1038/s41586-019-1272-6
5. Lennon AM, Buchanan AH, Kinde I, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science. 2020;369(6499):eabb9601. doi:10.1126/science.abb9601
6. Zviran A, Schulman RC, Shah M, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020;26(7):1114-1124. doi:10.1038/s41591-020-0915-3
7. Esfahani MS, Hamilton EG, Mehrmohamadi M, et al. Inferring gene expression from cell-free DNA fragmentation profiles. Nat Biotechnol. 2022;40(4):585-597. doi:10.1038/s41587-021-01115-0
8. Lianidou ES, Strati A, Markou A. Circulating tumor cells as promising novel biomarkers in solid cancers. Crit Rev Clin Lab Sci. 2014;51(3):160-171. doi:10.3109/10408363.2014.896316
9. Mohme M, Riethdorf S, Pantel K. Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape. Nat Rev Clin Oncol. 2017;14(3):155-167. doi:10.1038/nrclinonc.2016.144
10. Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926-930. doi:10.1126/science.aar3247
11. Mouliere F, Chandrananda D, Piskorz AM, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466):eaat4921. doi:10.1126/scitranslmed.aat4921
12. Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403):eaan2415. doi:10.1126/scitranslmed.aan2415
13. Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133. doi:10.1126/scitranslmed.aab0021
14. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451. doi:10.1038/nature22364
15. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548-554. doi:10.1038/nm.3519